
985
Downloads
47
Episodes
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Episodes
Jan 20, 2026
E16 - Prostate Cancer Surveillance
Jan 20, 2026
Jan 20, 2026
11 min
E16 | 12 min | Latest | Publication Link
- Podcast based on: Sandhu, K.; Lophatananon, A.; Gnanapragasam, V.J. The Impact of Endpoint Definitions on Predictors of Progression in Active Surveillance for Early Prostate Cancer. Cancers 2026, 18, 292. https://doi.org/10.3390/cancers18020292
Type: Article | Publication date: 17 January 2026 - Summary: Active surveillance (AS) is a critically important management strategy for men with favourable-prognosis prostate cancer. However, there is no standardised or internationally agreed-upon definition of a disease progression endpoint for when AS should stop. This has led to uncertainty regarding which baseline variables reliably predict progression. In the literature, there has also been a multitude of proposed biopsy and imaging metrics that are purported to predict AS progression. We utilised the STRATified CANcer Surveillance (STRATCANs) prospective AS database to assess the utility of different clinicopathological variables in predicting progression and against different contemporary AS endpoint definitions. In this study, we found that the AS endpoint definition appears to determine which variables predict progression. Neither the addition of biopsy nor imaging metrics added consistent incremental value in better predicting progression events. PSA density, in contrast, consistently predicted progression events across different endpoint definitions.
- Keywords: prostate cancer; active surveillance; STRATCANs; Cambridge prognostic group
License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.
Jan 20, 2026
11 min

No comments yet. Be the first to say something!